Article

Bausch & Lomb to delay regulatory filing

Rochester, NY-Bausch & Lomb will delay the regulatory filing for the intravitreal fluocinolone acetonide implant (Retisert), a treatment for diabetic macular edema (DME), for up to 3 years while the FDA reviews 12-month safety data of additional eyes treated with implants.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
Related Content
(Image credit: AdobeStock/ipopba) Robotic precision: Elevating the state of laser cataract surgery
August 13th 2025

Robotic precision: Elevating the state of laser cataract surgery

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
August 13th 2025

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/NicoElNino) Dialing in precision: Astigmatism management with arcuate incisions
August 13th 2025

Dialing in precision: Astigmatism management with arcuate incisions

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
August 13th 2025

(EyePod) From idea to impact: Navigating ophthalmic innovation

(Image credit: Wills Eye Hospital) Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer
August 13th 2025

Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer

(Image credit: AdobeStock/iQoncept) Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence
August 13th 2025

Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence

© 2025 MJH Life Sciences

All rights reserved.